| Name | Title | Contact Details |
|---|---|---|
Pedro Garcia |
Director of Human Resources | Profile |
Mokveld Valves BV is a Dutch manufacturer with a history dating back to 1922. Originally a machine repair shop, it evolved into a leader in high-pressure axial flow valve technology. The company specializes in valves designed for rapid and reliable isolation in severe-service applications, such as High-Integrity Pressure Protection Systems (HIPPS) and Emergency Shut Down (ESD) systems. Mokvelds product range includes axial flow valves, axial control valves, angle choke valves, and axial choke valves, all engineered for demanding environments. Their valves are known for features like bubble-tight bi-directional sealing and the ability to operate under full differential pressure. Mokveld serves a global customer base in the energy sector, including oil and gas production, transmission, and processing, as well as the water industry. The company is recognized for its commitment to reliability, safety, and environmental performance.
Our lender-placed insurance, blanket insurance, and specialty insurance programs provide comprehensive coverage to financial institutions, government entities, property investors, and property & casualty agencies. Proctor Loan Protectors service solutions are powered by superior customer service, proprietary innovations, technology, and an experienced team. We perform insurance tracking, which includes policy procurement, mail processing, disbursement facilitation, and an award-winning borrower call center.
Safety National is a prominent specialty insurance and reinsurance provider with over 80 years of experience. As a wholly-owned subsidiary of Tokio Marine Holdings, Inc., it benefits from the strength of one of the worlds top insurance groups. The company focuses on building strong relationships and providing long-term solutions for its customers. Safety National specializes in long-term insurance and reinsurance solutions, particularly in managing high-exposure claims. It offers MAP Client Services®, a suite of online risk control resources designed to help policyholders improve their safety and compliance programs. The company is highly rated by major financial agencies, holding an A++ rating from A.M. Best and an A+ rating from Standard & Poor’s. The corporate culture at Safety National emphasizes diversity, equity, and inclusion, aiming to reflect the communities it serves. The company is committed to corporate social responsibility through sustainability practices and charitable efforts. Safety National actively seeks talented individuals who share its dedication to excellence and growth.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.